Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease. The Company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences supplies its products worldwide.
Website: edwards.com


  • Bad financial results growth rate -4.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-0.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 5.3% (LTM)
  • Share price is 40.7% higher than minimum and 12.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (29.2x vs 29.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $5.0 mln (-0.009% of cap.)

Key Financials (Download financials)

Ticker: EW
Share price, USD:  (+0.1%)83.97
year average price 76.07  


year start price 73.97 2024-12-12

min close price 67.07 2025-04-08

max close price 86.82 2025-11-25

current price 83.97 2025-12-11
Common stocks: 621 751 997

Dividend Yield:  0.0%
FCF Yield LTM: 5.3%
EV / LTM EBITDA: 29.2x
EV / EBITDA annualized: 28.4x
Last revenue growth (y/y):  -11.6%
Last growth of EBITDA (y/y):  +2.6%
Historical revenue growth:  +1.5%
Historical growth of EBITDA:  -2.4%
EV / Sales: 8.9x
Margin (EBITDA LTM / Revenue): 30.4%

Target EV / EBITDA (hist percentile): 29.0x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 52 209
Net Debt ($m): -3 136
EV (Enterprise Value): 49 073
EBITDA LTM (млн $): 1 682
EV / LTM EBITDA: 29.2x
Price to Book: 5.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-11zacks.com

Should You Continue to Hold EW Stock in Your Portfolio?

2025-12-11seekingalpha.com

Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript

2025-11-30prnewswire.com

HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

2025-11-29defenseworld.net

Berry Wealth Group LP Makes New Investment in Edwards Lifesciences Corporation $EW

2025-11-09businesswire.com

Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease

2025-10-30seekingalpha.com

Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript

2025-10-30reuters.com

Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

2025-10-27globenewswire.com

EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW

2025-10-27businesswire.com

Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025

2025-10-23businesswire.com

Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EW EW EW EW EW EW EW EW EW EW EW
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-07-31 2024-04-29 2024-02-12 2023-10-27 2023-07-28 2023-04-28 2023-02-13 2022-10-28
acceptedDate 2025-11-05 16:12:51 2025-08-06 16:04:14 2024-11-06 16:20:18 2024-07-31 16:14:58 2024-04-29 16:06:19 2024-02-12 16:47:29 2023-10-27 16:49:16 2023-07-28 16:32:01 2023-04-28 16:49:04 2023-02-13 16:32:19 2022-10-28 16:21:34
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 553M 1 532M 1 354M 1 386M 1 598M 1 534M 1 481M 1 530M 1 460M 1 348M 1 319M
costOfRevenue 345M 343M 263M 298M 384M 357M 350M 343M 330M 258M 254M
grossProfit 1 210M 1 190M 1 092M 1 088M 1 214M 1 177M 1 131M 1 187M 1 130M 1 090M 1 065M
grossProfitRatio 0.779 0.776 0.806 0.785 0.76 0.767 0.763 0.776 0.774 0.809 0.808
researchAndDevelopmentExpenses 281M 276M 253M 273M 285M 270M 270M 270M 261M 232M 234M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 515M 502M 421M 451M 490M 479M 440M 469M 436M 411M 377M
otherExpenses -11M -20M 24M 2M -1M -6M 6M 2M 2M 0 0
operatingExpenses 785M 759M 699M 723M 776M 749M 710M 739M 698M 643M 611M
costAndExpenses 1 128M 1 101M 960M 1 021M 1 161M 1 106M 1 060M 1 082M 1 027M 901M 865M
interestIncome 39M 37M 24M 16M 0 7M 15M 9M 9M 35M 0
interestExpense 0 0 0 0 0 28M 0 0 -10M 8M 7M
depreciationAndAmortization 39M 38M 35M 40M 39M 37M 4M -2M 88M -1M 47M
ebitda 388M 400M 429M 417M 526M 368M 423M 569M 477M 447M 450M
ebitdaratio 0.25 0.261 0.317 0.292 0.329 0.24 0.286 0.372 0.327 0.331 0.341
operatingIncome 425M 431M 394M 365M 438M 400M 418M 327M 388M 448M 402M
operatingIncomeRatio 0.274 0.281 0.291 0.263 0.274 0.261 0.283 0.214 0.266 0.332 0.305
totalOtherIncomeExpensesNet -77M -31M 9M 18M -28M -24M 4M -119M 10M 12M 5M
incomeBeforeTax 348M 400M 403M 387M 409M 422M 439M 339M 399M 459M 407M
incomeBeforeTaxRatio 0.224 0.261 0.297 0.279 0.256 0.275 0.297 0.221 0.273 0.341 0.309
incomeTaxExpense 56M 64M 41M 20M 58M 52M 56M 33M 58M 61M 64M
netIncome 291M 330M 3 071M 366M 352M 370M 385M 307M 341M 398M 344M
netIncomeRatio 0.187 0.215 2.267 0.264 0.22 0.241 0.26 0.201 0.233 0.295 0.26
eps 0.5 0.57 5.14 0.61 0.58 0.61 0.63 0.51 0.56 0.65 0.55
epsdiluted 0.5 0.56 5.13 0.61 0.58 0.61 0.63 0.5 0.56 0.65 0.55
weightedAverageShsOut 585M 587M 597M 602M 602M 605M 607M 607M 608M 613M 620M
weightedAverageShsOutDil 586M 588M 598M 604M 604M 607M 610M 610M 611M 616M 625M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EW EW EW EW EW EW EW EW EW EW EW
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-07-31 2024-04-29 2024-02-12 2023-10-27 2023-07-28 2023-04-28 2023-02-13 2022-10-28
acceptedDate 2025-11-05 16:12:51 2025-08-06 16:04:14 2024-11-06 16:20:18 2024-07-31 16:14:58 2024-04-29 16:06:19 2024-02-12 16:47:29 2023-10-27 16:49:16 2023-07-28 16:32:01 2023-04-28 16:49:04 2023-02-13 16:32:19 2022-10-28 16:21:34
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 2 686M 3 273M 3 676M 1 648M 1 225M 1 144M 1 410M 1 043M 873M 769M 1 248M
shortTermInvestments 1 156M 789M 770M 345M 473M 501M 454M 467M 382M 446M 491M
cashAndShortTermInvestments 3 842M 4 062M 4 446M 1 993M 1 698M 1 645M 1 864M 1 509M 1 254M 1 215M 1 739M
netReceivables 893M 903M 812M 834M 877M 837M 802M 817M 779M 699M 661M
inventory 1 141M 1 142M 1 104M 1 025M 1 207M 1 168M 1 032M 980M 914M 876M 758M
otherCurrentAssets 483M 471M 366M 667M 389M 239M 236M 217M 190M 196M 356M
totalCurrentAssets 6 359M 6 577M 6 728M 4 516M 4 171M 4 036M 4 068M 3 647M 3 257M 3 096M 3 514M
propertyPlantEquipmentNet 1 840M 1 826M 1 780M 1 733M 1 866M 1 843M 1 772M 1 747M 1 735M 1 725M 1 654M
goodwill 1 769M 1 777M 1 605M 1 151M 1 253M 1 254M 1 297M 1 300M 1 308M 1 164M 1 159M
intangibleAssets 1 131M 1 173M 956M 417M 447M 428M 430M 431M 447M 285M 267M
goodwillAndIntangibleAssets 2 899M 2 950M 2 561M 1 568M 1 700M 1 682M 1 727M 1 731M 1 755M 1 450M 1 425M
longTermInvestments 275M 299M 320M 385M 456M 584M 705M 856M 1 067M 1 239M 1 381M
taxAssets 1 100M 1 082M 888M 833M 777M 755M 652M 611M 544M 484M 348M
otherNonCurrentAssets 800M 756M 694M 1 065M 768M 464M 447M 412M 294M 299M 317M
totalNonCurrentAssets 6 913M 6 912M 6 244M 5 583M 5 566M 5 328M 5 303M 5 357M 5 394M 5 197M 5 124M
otherAssets 0 0 0 1 1 0 0 0 0 0 0
totalAssets 13 272M 13 489M 12 971M 10 099M 9 736M 9 363M 9 371M 9 004M 8 651M 8 293M 8 638M
accountPayables 165M 162M 173M 186M 1 086M 201M 191M 193M 181M 202M 155M
shortTermDebt 27M 26M 24M 43M 25M 25M 24M 24M 25M 26M 24M
taxPayables 0 0 1M 47M 156M 122M 81M 81M 143M 96M 93M
deferredRevenue 0 37M 66M 47M -1 086M 954M -191M -193M 0 484M 0
otherCurrentLiabilities 1 396M 1 180M 1 680M 941M 1 086M 15M 1 215M 1 133M 876M 311M 740M
totalCurrentLiabilities 1 588M 1 405M 1 944M 1 217M 1 111M 1 195M 1 239M 1 157M 1 082M 1 022M 918M
longTermDebt 674M 677M 683M 672M 597M 670M 667M 660M 663M 666M 663M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 443M 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 363M 801M 733M 706M 842M 778M 738M 740M 845M 798M 1 324M
totalNonCurrentLiabilities 1 479M 1 478M 1 416M 1 378M 1 439M 1 448M 1 405M 1 400M 1 507M 1 463M 1 503M
otherLiabilities 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 102M 105M 109M 96M 77M 98M 94M 88M 91M 95M 91M
totalLiabilities 3 067M 2 882M 3 360M 2 595M 2 550M 2 644M 2 644M 2 558M 2 589M 2 486M 2 420M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 658M 658M 654M 654M 652M 651M 650M 649M 647M 646M 646M
retainedEarnings 14 149M 13 858M 12 781M 9 711M 9 344M 8 992M 8 623M 8 238M 7 931M 7 590M 7 192M
accumulatedOtherComprehensiveIncomeLoss -250M -264M -253M -220M -233M -243M -250M -256M -255M -255M -256M
othertotalStockholdersEquity -4 352M -3 706M -3 638M -2 707M -2 645M -2 750M -2 365M -2 256M -2 344M -2 175M -1 364M
totalStockholdersEquity 10 205M 10 545M 9 546M 7 437M 7 118M 6 650M 6 658M 6 376M 5 978M 5 807M 6 218M
totalEquity 10 205M 10 607M 9 611M 7 505M 7 186M 6 719M 6 727M 6 447M 5 978M 5 807M 6 218M
totalLiabilitiesAndStockholdersEquity 13 272M 13 489M 12 971M 10 099M 9 736M 9 363M 9 371M 9 004M 8 651M 8 293M 8 638M
minorityInterest 0 61M 66M 67M 69M 69M 70M 71M 84M 0 0
totalLiabilitiesAndTotalEquity 13 272M 13 489M 12 971M 10 099M 9 736M 9 363M 9 371M 9 004M 8 651M 8 293M 8 638M
totalInvestments 1 431M 1 088M 1 089M 730M 929M 1 084M 1 158M 1 323M 1 448M 1 685M 1 872M
totalDebt 700M 703M 707M 693M 699M 695M 691M 685M 688M 691M 687M
netDebt -1 985M -2 570M -2 970M -955M -525M -449M -719M -358M -185M -78M -561M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EW EW EW EW EW EW EW EW EW EW EW
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-07-31 2024-04-29 2024-02-12 2023-10-27 2023-07-28 2023-04-28 2023-02-13 2022-10-28
acceptedDate 2025-11-05 16:12:51 2025-08-06 16:04:14 2024-11-06 16:20:18 2024-07-31 16:14:58 2024-04-29 16:06:19 2024-02-12 16:47:29 2023-10-27 16:49:16 2023-07-28 16:32:01 2023-04-28 16:49:04 2023-02-13 16:32:19 2022-10-28 16:21:34
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 290M 332M 3 069M 368M 351M 370M 384M 306M 341M 398M 344M
depreciationAndAmortization 39M 38M 35M 40M 39M 37M 37M 36M 35M 35M 35M
deferredIncomeTax -18M -21M -123M -66M -36M -91M -46M -83M -52M -106M -46M
stockBasedCompensation 41M 38M 42M 44M 45M 31M 33M 37M 39M 28M 30M
changeInWorkingCapital 84M -142M 480M -21M -459M -216M -12M -241M -57M -85M -115M
accountsReceivables 13M -25M 47M 23M -55M -41M -28M -224M -78M -6M 0
inventory -2M 42M -41M -94M -70M -99M -76M -81M -33M -62M -65M
accountsPayables 226M 104M 30M 152M -89M 33M 36M 121M -45M 34M 26M
otherWorkingCapital -154M -262M 444M -101M -267M -109M 56M -58M 99M -51M -75M
otherNonCashItems 138M 46M -3 151M 50M 7M 7M 17M -21M 8M 12M 62M
netCashProvidedByOperatingActivities 574M 290M 352M 372M -54M 137M 412M 34M 314M 283M 310M
investmentsInPropertyPlantAndEquipment -58M -49M -32M -85M -85M -102M -55M -48M -62M -89M -60M
acquisitionsNet 0 3M 3 164M 0 0 46M 55M 48M -141M 0 0
purchasesOfInvestments -1 031M -630M -528M -13M -13M -59M -10M -7M -31M -83M -345M
salesMaturitiesOfInvestments 670M 594M 176M 247M 167M 137M 180M 134M 264M 274M 224M
otherInvestingActivites -9M -90M -78M -24M -5M -9M -82M -57M -30M -7M -20M
netCashUsedForInvestingActivites -428M -172M 2 702M 125M 63M 14M 89M 70M 500 000 95M -202M
debtRepayment 0 0 0 0 0 -300 000 0 0 0 -100 000 0
commonStockIssued 0 57M 0 0 62M 33M 34M 0 0 0 0
commonStockRepurchased 157M -6M -901M -158M -200 000 -448M -174M -8M -249M -866M -100M
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -897M 1 000 000 -76M 62M -200 000 35M -3M 60M 43M 28M 31M
netCashUsedProvidedByFinancingActivities -740M 53M -977M -97M 62M -413M -143M 52M -207M -838M -70M
effectOfForexChangesOnCash -1 000 000 -30M -52M 29M 10M -3M 9M 15M -4M -18M 10M
netChangeInCash -595M 141M 2 035M 420M 81M -266M 366M 171M 104M -479M 49M
cashAtEndOfPeriod 2 695M 3 290M 3 683M 1 648M 1 229M 1 148M 1 414M 1 048M 876M 773M 1 252M
cashAtBeginningOfPeriod 3 290M 3 149M 1 648M 1 228M 1 148M 1 414M 1 048M 876M 773M 1 252M 1 203M
operatingCashFlow 574M 290M 352M 372M -54M 137M 412M 34M 314M 283M 310M
capitalExpenditure -58M -49M -32M -85M -85M -102M -55M -48M -62M -89M -60M
freeCashFlow 516M 241M 320M 286M -139M 35M 356M -14M 253M 194M 250M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-24 ET (fiscal 2025 q2)
2025 q1
2025-04-23 ET (fiscal 2025 q1)
2024 q4
2025-02-11 ET (fiscal 2024 q4)
2024 q3
2024-10-24 ET (fiscal 2024 q3)
2024 q2
2024-07-24 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-26 ET (fiscal 2023 q2)
2023 q1
2023-04-26 ET (fiscal 2023 q1)
2022 q4
2023-01-31 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-26 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-24 20:21 ET
Edwards Lifesciences Reports Third Quarter Results
2024-10-24 13:04 ET
EW DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before December 13, 2024
2024-10-24 00:10 ET
EDWARDS LIFESCIENCES DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on December 13, 2024
2024-10-18 15:08 ET
Edwards Lifesciences Deadline to Lead in Securities Fraud Lawsuit is December 13, 2024 - Contact Kaplan Fox & Kilsheimer LLP
2024-10-17 13:08 ET
Deadline to Lead in Securities Fraud Lawsuit Against Edwards Lifesciences Corp. (EW) is December 13, 2024 - Contact Kaplan Fox & Kilsheimer LLP
2024-10-17 11:05 ET
Edwards Lifesciences to Host Earnings Conference Call on October 24, 2024
2024-09-28 20:12 ET
ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM
2024-09-03 20:30 ET
Edwards Lifesciences Completes Sale of Critical Care
2024-08-31 16:35 ET
CORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
2024-08-21 11:00 ET
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference
2024-07-24 20:15 ET
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
2024-07-24 20:15 ET
Edwards Lifesciences Reports Second Quarter Results
2024-07-17 11:05 ET
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
2024-07-15 13:00 ET
Edwards Lifesciences to Acquire Innovalve
2024-06-05 15:45 ET
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
2024-06-03 10:30 ET
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
2024-06-03 10:30 ET
Edwards Lifesciences to Sell Critical Care to BD
2024-05-08 23:21 ET
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
2024-04-25 20:15 ET
Edwards Lifesciences Reports First Quarter Results
2024-04-18 11:10 ET
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
2024-04-07 20:30 ET
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
2024-03-11 18:00 ET
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
2024-02-23 12:05 ET
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
2024-02-06 21:15 ET
Edwards Lifesciences Reports Fourth Quarter Results
2024-02-02 12:00 ET
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
2024-01-30 12:05 ET
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
2024-01-02 14:00 ET
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 13:30 ET
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
2023-10-26 19:06 ET
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
2023-10-26 18:00 ET
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
2023-10-25 20:15 ET
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
2023-10-24 18:00 ET
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
2023-10-19 12:30 ET
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
2023-10-18 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
2023-08-28 12:10 ET
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
2023-07-26 20:15 ET
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
2023-07-19 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023
2023-05-17 08:30 ET
DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY
2023-05-08 00:00 ET
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA
2023-04-26 20:15 ET
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS
2023-04-19 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023
2023-03-06 14:00 ET
EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS
2023-01-31 21:15 ET
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
2023-01-24 12:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023
2023-01-05 14:05 ET
EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2022-12-08 13:01 ET
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
2022-12-08 13:00 ET
EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN
2022-11-27 15:25 ET
EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT
2022-11-01 13:00 ET
EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE
2022-10-27 20:15 ET
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
2022-10-20 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022
2022-09-17 15:30 ET
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL
2022-09-15 13:00 ET
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION
2022-09-12 13:05 ET
EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL
2022-08-17 12:30 ET
EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK
2022-07-28 20:15 ET
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
2022-07-21 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022
2022-05-23 12:10 ET
EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE
2022-05-16 13:15 ET
EDWARDS ANNOUNCES KEY EVENTS FOR EUROPCR 2022
2022-04-26 20:15 ET
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS
2022-04-19 11:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2022
2022-03-31 13:15 ET
EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES
2022-01-26 21:15 ET
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
2022-01-19 12:05 ET
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022
2022-01-05 13:10 ET
EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2021-12-20 14:05 ET
EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT
2021-12-08 14:05 ET
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
2021-11-06 17:47 ET
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
2021-11-05 15:20 ET
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
2021-10-27 20:15 ET
Edwards Lifesciences Reports Third Quarter Results
2021-10-20 11:05 ET
Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021
2021-07-29 20:15 ET
Edwards Lifesciences Reports Second Quarter Results
2021-07-22 19:15 ET
Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
2021-07-22 11:05 ET
Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021
2021-06-01 20:15 ET
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
2021-05-20 20:05 ET
Neovasc Provides Update on German Litigation
2021-05-18 20:15 ET
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
2021-05-18 20:15 ET
Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
2021-05-05 13:15 ET
Edwards Announces Updates From Annual Meeting
2021-04-21 19:00 ET
Providence Partners with Edwards Lifesciences, Cities of Irvine, Santa Ana, Costa Mesa and Tustin to Open Two Free Mass COVID-19 Vaccination Clinics
2021-04-20 20:15 ET
Edwards Lifesciences Reports First Quarter Results
2021-04-13 11:05 ET
Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021
2021-01-31 21:51 ET
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
2021-01-27 21:15 ET
Edwards Lifesciences Reports Fourth Quarter Results
2021-01-13 12:05 ET
Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021
2020-12-21 14:05 ET
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
2020-12-10 14:05 ET
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
2020-10-21 20:15 ET
Edwards Lifesciences Reports Third Quarter Results
2020-10-07 14:05 ET
Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020
2020-07-23 20:15 ET
Edwards Lifesciences Reports Second Quarter Results
2020-07-15 12:30 ET
Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors
2020-07-15 12:30 ET
Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
2020-07-13 20:15 ET
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
2020-07-09 14:05 ET
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2020
2020-06-08 14:37 ET
Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China
2020-05-18 04:00 ET
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
2020-05-07 20:15 ET
Edwards Announces Updates From Annual Meeting
2020-05-05 12:15 ET
Edwards Lifesciences Announces May 2020 Investor Conference Schedule
2020-04-27 20:30 ET
Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients
2020-04-23 20:15 ET
Edwards Lifesciences Reports First Quarter Results
2020-04-13 20:30 ET
Edwards Lifesciences To Hold Virtual Annual Meeting Of Stockholders
2020-04-09 14:05 ET
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2020
2020-03-29 13:00 ET
Edwards SAPIEN 3 Valve Shows Excellent Results At 2 Years
2020-03-28 14:00 ET
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19
2020-02-24 13:15 ET
Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference
2020-02-21 13:31 ET
Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients
2020-01-30 21:15 ET
Edwards Lifesciences Reports Fourth Quarter Results
2020-01-16 15:05 ET
Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020
2019-12-05 12:30 ET
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
2019-11-06 06:00 ET
Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
2019-10-23 20:15 ET
Edwards Lifesciences Reports Third Quarter Results
2019-03-16 17:59 ET
Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
2019-03-11 12:30 ET
Edwards Lifesciences Announces Strategic Investments
2019-02-19 21:15 ET
Edwards PASCAL Transcatheter System Receives CE Mark
2019-02-12 20:34 ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of CAS Medical Systems, Inc.
ET
Edwards Lifesciences Reports Third Quarter Results
ET
Edwards Lifesciences Announces CFO Transition Plan
ET
Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion of Market Capitalization - Hagens Berman
ET
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
ET
Investor Reminder (EW): Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Investors of December 13, 2024 Deadline
ET
Investor Reminder (EW): Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Investors of December 13, 2024 Deadline
ET
EW DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit
ET
EW DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit
ET
EW Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Edwards Lifesciences Corporation (EW)
ET
EW Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Edwards Lifesciences Corporation (EW)
ET
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
ET
EW Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifescience Corporation (EW) Investors of Deadline and Encourages Investors with Losses to Contact the Firm
ET
EW Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation (EW) Investors of Deadline and Encourages Investors with Losses to Contact the Firm
ET
Lead Plaintiff Deadline on December 13, 2024 for EW Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
ET
EW DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Investors of Deadline and Encourages Investors with Losses to Contact the Firm
ET
EW DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Investors of Deadline and Encourages Investors with Losses to Contact the Firm
ET
Edwards Lifesciences Corporation Investors: December 13, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
ET
Edwards Lifesciences Corporation Investors: December 13, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
ET
EW DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit
ET
EW DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit
ET
Edwards Lifesciences (EW) Investors Alerted to Today's Lead Plaintiff Deadline in Class Action Lawsuit Over TAVM Platform Disclosures - Hagens Berman
ET
Edwards Lifesciences (EW) Investors Alerted to Today's Lead Plaintiff Deadline in Class Action Lawsuit Over TAVM Platform Disclosures - Hagens Berman
ET
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ET
Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025
ET
Edwards Lifesciences Reports Fourth Quarter Results
ET
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
ET
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
ET
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
ET
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
ET
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
ET
Edwards Lifesciences Reports First Quarter Results
ET
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
ET
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
ET
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
ET
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025
ET
Edwards Lifesciences Reports Second Quarter Results
ET
Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve
ET
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
ET
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
ET
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
ET
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
ET
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025

SEC forms

Show financial reports only

SEC form 10
2025-11-05 21:12 ET
Edwards Lifesciences reported for 2025 q3
SEC form 8
2025-10-30 20:18 ET
Edwards Lifesciences reported for 2025 q3
SEC form 8
2025-10-30 20:18 ET
Edwards Lifesciences published news for 2025 q3
SEC form 8
2025-08-19 20:17 ET
Edwards Lifesciences published news for 2025 q2
SEC form 8
2025-08-19 20:17 ET
Edwards Lifesciences published news for 2025 q2
SEC form 10
2025-08-06 20:04 ET
Edwards Lifesciences reported for 2025 q2
SEC form 8
2025-08-06 17:43 ET
Edwards Lifesciences published news for 2025 q2
SEC form 8
2025-08-06 17:43 ET
Edwards Lifesciences published news for 2025 q2
SEC form 8
2025-07-24 20:23 ET
Edwards Lifesciences published news for 2025 q2
SEC form 8
2025-07-24 20:23 ET
Edwards Lifesciences reported for 2025 q2
SEC form 10
2025-05-06 20:13 ET
Edwards Lifesciences published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Edwards Lifesciences reported for 2025 q1
SEC form 8
2025-04-23 20:33 ET
Edwards Lifesciences reported for 2025 q1
SEC form 8
2025-04-23 20:33 ET
Edwards Lifesciences published news for 2025 q1
SEC form 10
2025-02-28 21:50 ET
Edwards Lifesciences published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Edwards Lifesciences published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Edwards Lifesciences reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Edwards Lifesciences published news for 2024 q4
SEC form 10
2024-11-06 16:20 ET
Edwards Lifesciences reported for 2024 q3
SEC form 8
2024-10-24 16:28 ET
Edwards Lifesciences published news for 2024 q3
SEC form 8
2024-10-24 16:28 ET
Edwards Lifesciences published news for 2024 q3
SEC form 10
2024-07-31 00:00 ET
Edwards Lifesciences published news for 2024 q2
SEC form 8
2024-07-24 16:26 ET
Edwards Lifesciences published news for 2024 q2
SEC form 8
2024-07-24 16:26 ET
Edwards Lifesciences reported for 2024 q2
SEC form 8
2024-07-24 16:26 ET
Edwards Lifesciences published news for 2024 q2
SEC form 10
2024-04-29 00:00 ET
Edwards Lifesciences published news for 2024 q1
SEC form 8
2024-04-25 16:23 ET
Edwards Lifesciences reported for 2024 q1
SEC form 8
2024-04-25 16:23 ET
Edwards Lifesciences published news for 2024 q1
SEC form 10
2024-02-12 00:00 ET
Edwards Lifesciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Edwards Lifesciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Edwards Lifesciences published news for 2023 q4
SEC form 10
2023-10-27 00:00 ET
Edwards Lifesciences published news for 2023 q3
SEC form 8
2023-10-25 16:32 ET
Edwards Lifesciences reported for 2023 q3
SEC form 10
2023-07-28 00:00 ET
Edwards Lifesciences published news for 2023 q2
SEC form 6
2023-07-26 16:22 ET
Edwards Lifesciences reported for 2023 q2
SEC form 8
2023-07-26 00:00 ET
Edwards Lifesciences published news for 2023 q2
SEC form 6
2023-06-15 16:11 ET
Edwards Lifesciences published news for 2023 q1
SEC form 6
2023-06-15 16:09 ET
Edwards Lifesciences published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
Edwards Lifesciences published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
Edwards Lifesciences published news for 2023 q1
SEC form 6
2023-03-28 16:19 ET
Edwards Lifesciences published news for 2022 q4
SEC form 6
2023-02-21 16:30 ET
Edwards Lifesciences published news for 2022 q4
SEC form 10
2023-02-13 16:32 ET
Edwards Lifesciences reported for 2022 q4
SEC form 10
2023-02-13 00:00 ET
Edwards Lifesciences reported for 2022 q4
SEC form 6
2023-01-31 16:31 ET
Edwards Lifesciences published news for 2022 q4
SEC form 8
2023-01-31 00:00 ET
Edwards Lifesciences reported for 2022 q4
SEC form 6
2022-12-08 17:27 ET
Edwards Lifesciences published news for 2022 q3
SEC form 6
2022-11-01 09:13 ET
Edwards Lifesciences published news for 2022 q3
SEC form 10
2022-10-28 16:21 ET
Edwards Lifesciences reported for 2022 q3
SEC form 10
2022-10-28 00:00 ET
Edwards Lifesciences reported for 2022 q3
SEC form 6
2022-10-27 16:21 ET
Edwards Lifesciences published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Edwards Lifesciences reported for 2022 q3
SEC form 10
2022-07-29 16:55 ET
Edwards Lifesciences reported for 2022 q2
SEC form 10
2022-07-29 00:00 ET
Edwards Lifesciences reported for 2022 q2
SEC form 6
2022-07-28 16:38 ET
Edwards Lifesciences published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Edwards Lifesciences reported for 2022 q2
SEC form 6
2022-07-21 16:20 ET
Edwards Lifesciences published news for 2022 q2
SEC form 6
2022-06-16 16:11 ET
Edwards Lifesciences published news for 2022 q1
SEC form 6
2022-06-16 16:08 ET
Edwards Lifesciences published news for 2022 q1
SEC form 6
2022-05-04 17:19 ET
Edwards Lifesciences published news for 2022 q1
SEC form 10
2022-04-28 16:08 ET
Edwards Lifesciences published news for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Edwards Lifesciences reported for 2022 q1
SEC form 6
2022-04-26 16:24 ET
Edwards Lifesciences published news for 2022 q1
SEC form 8
2022-04-26 00:00 ET
Edwards Lifesciences reported for 2022 q1
SEC form 6
2022-03-22 16:02 ET
Edwards Lifesciences published news for 2021 q4
SEC form 10
2022-02-14 16:15 ET
Edwards Lifesciences published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
Edwards Lifesciences published news for 2021 q4
SEC form 6
2022-01-26 16:37 ET
Edwards Lifesciences published news for 2021 q4
SEC form 8
2022-01-26 00:00 ET
Edwards Lifesciences published news for 2021 q4
SEC form 10
2021-10-29 16:56 ET
Edwards Lifesciences published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
Edwards Lifesciences published news for 2021 q3
SEC form 6
2021-10-27 16:29 ET
Edwards Lifesciences published news for 2021 q3
SEC form 8
2021-10-27 00:00 ET
Edwards Lifesciences published news for 2021 q3
SEC form 10
2021-07-30 16:06 ET
Edwards Lifesciences published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
Edwards Lifesciences published news for 2021 q2
SEC form 6
2021-07-29 16:33 ET
Edwards Lifesciences published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Edwards Lifesciences published news for 2021 q2
SEC form 6
2021-07-15 17:14 ET
Edwards Lifesciences published news for 2021 q2
SEC form 6
2021-06-21 09:06 ET
Edwards Lifesciences published news for 2021 q1
SEC form 6
2021-06-21 09:05 ET
Edwards Lifesciences published news for 2021 q1
SEC form 6
2021-05-05 16:56 ET
Edwards Lifesciences published news for 2021 q1
SEC form 10
2021-04-28 16:09 ET
Edwards Lifesciences published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
Edwards Lifesciences published news for 2021 q1
SEC form 6
2021-04-20 16:26 ET
Edwards Lifesciences published news for 2021 q1
SEC form 8
2021-04-20 00:00 ET
Edwards Lifesciences published news for 2021 q1
SEC form 6
2021-03-23 16:14 ET
Edwards Lifesciences published news for 2020 q4
SEC form 10
2021-02-12 16:58 ET
Edwards Lifesciences published news for 2020 q4
SEC form 6
2021-01-27 16:36 ET
Edwards Lifesciences published news for 2020 q4
SEC form 10
2020-10-23 19:57 ET
Edwards Lifesciences published news for 2020 q3
SEC form 6
2020-10-21 17:36 ET
Edwards Lifesciences published news for 2020 q3